LEO Pharma

Privately held: no public share price

Assets

(6 total)
6Total Assets
5Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
brodalumab(Siliq)
Approved
IL-17 receptor AMonoclonal antibody
Psoriasis
Approved
Vitamin D receptor + Glucocorticoid receptorSmall molecule
Psoriasis
Approved
Vitamin D receptor + Glucocorticoid receptorSmall molecule
Psoriasis
spesolimab(Spevigo)
Approved
IL-36 receptorMonoclonal antibody
PsoriasisHidradenitis Suppurativa
Approved
IL-13Monoclonal antibody
Atopic Dermatitis
Phase 2
IL-22 receptor subunit alpha-1 (IL-22RA1)Monoclonal antibody
Atopic Dermatitis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
spesolimab · SpevigoPhase 2Generalized Pustular Psoriasis
Est. primary completion 2027-09-30 · NCT03886246 · CT.gov ↗
What to watch
November 2027 (1)
spesolimab · SpevigoPhase 3Pyoderma Gangrenosum
Est. primary completion 2027-11-12 · NCT06624670 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 November 2026ApprovaldelgocitinibNMPA approves Anzupgo cream in chronic hand eczema
CN, NMPA · Source ↗
9 July 2026Topline resulttralokinumabPhase 2 TRAPEDS-1 results for tralokinumab in children

Financial reports

No financial reports recorded.